Join a Legacy of Innovation 110 Years and Counting!
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people globally by leveraging our world-class science and technology. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. Under the Group’s 2025 Vision to become a “Global Pharma Innovator with Competitive Advantage in Oncology,” Daiichi Sankyo is primarily focused on providing novel therapies in oncology, as well as other research areas centered around rare diseases and immune disorders.
Disease Area Strategy Team (DAST) is a highly matrixed cross-functional and cross-regional team including R&D, commercial and Medical Affairs functions. The two DAST teams are tasked to monitor changes and trends in the therapeutic landscape of Breast Cancer or Lung Cancer and provide end-to-end strategic leadership and disease area expertise across the ADCs portfolio plus emerging multiple assets. The Global Oncology Medical Affairs (GOMA) Disease Area Strategy Lead will be a core member of the DAST and will work collaboratively to provide strategic input and medical leadership to the cross-functional team. The GOMA Disease Area Strategy Lead is a critical senior position, accountable for providing strategic direction and matrix leadership to define the cross-asset Breast or Lung cancer medical plan. The GOMA DAST Lead will be responsible for the alignment, coordination and implementation of overall disease strategic medical initiatives that sit above individual assets. The GOMA DAST Lead will be accountable for working closely with the asset teams to establish and lead the overall Evidence Generation strategy for Breast or Lung cancer.
- Incorporate GOMA perspective into broader disease area strategies developed by the DAST with a goal to provide guidance and prioritization to asset teams about opportunities and areas of unmet medical need and generate strategically aligned development strategies
- Lead the development of above-asset medical strategies for Breast or Lung cancer.
- Collaborate with asset teams and cross-functional partners to deliver the above asset scientific narrative for Breast or Lung cancer.
- Work in partnership with GMAT Leads to ensure that the DAST strategic expertise and input is aligned and integrated into the asset-level strategies and Medical Plans.
- Work with Patient Advocacy Leads to incorporate the patient voice into the DAST Strategy.
- Contribute to input-seeking activities (Field Medical Affairs Insights, competitive intelligence, advisory boards, etc.) and act on appropriate insights. Lead cross-asset advisory board planning and execution.
- Lead the overall evidence generation strategy for breast or lung cancer.
Qualifications: Successful candidates will be able to meet the qualifications below with or without a reasonable accommodation.
Education Qualifications (from an accredited college or university)
- PharmD, PhD or MD required
- Minimum of 10 years of pharmaceutical industry experience. Experience with oncology medical strategies is required.
- Knowledge of oncology basic science, mechanisms of action, biomarkers, clinical treatment landscapes in breast or lung cancer is essential; required
- Strong background in evidence generation required, with previous study leadership in clinical development or medical affairs required
- Launch experience is required
Daiichi Sankyo, Inc. is an equal opportunity/affirmative action employer. Qualified applicants will receive consideration for employment without regard to sex, gender identity, sexual orientation, race, color, religion, national origin, disability, protected veteran status, age, or any other characteristic protected by law.
- Clinical Development
- Clinical Works